

66 (1) (2)

45

31

21

14

6.5

Fig. 1A

66 (1) (2) (3) (4)

45

31

21

14

6.5

Fig. 1B




Fig. 1C




Fig. 3A




Fig. 3B




Fig. 3C

Saliva IgA anti-holotoxin (specific / total x 100)




Fig. 4A

Vaginal IgA anti-holotoxin (specific / total x 100)




Fig. 4B

Immunogen/ Group

- ☐ SBR-CTA2/B
- ▨ SBR-LT-IIaA2/B

Immunogen/Group

- ☐ SBR-CTA2/B
- ▨ SBR-LT-IIaA2/B

Immunogen/Group

▨ SBR-CTA2/B

▩ SBR-LT-IIaA2/B




Fig. 4C

Immunogen/Group

▨ SBR-CTA2/B

▩ SBR-LT-IIaA2/B




Fig. 4D




Fig. 5A

B cell treatment:




Fig. 5B




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D




Fig. 6E




Fig. 7

Ab Treatment:




Fig. 8A

Ab Treatment:




Fig. 8B

Ab Treatment:




Fig. 8C

Ab Treatment:




Fig. 8D